Pharmacyclics and Janssen Biotech won full US FDA approval and an expanded the label for their drug Imbruvica (ibrutinib) in the treatment of chronic lymphocytic leukemia (CLL) just five months after getting accelerated approval for the Bruton's tyrosine kinase (BTK) inhibitor for previously treated CLL patients.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?